First Turn Management LLC Makes New Investment in Fulcrum Therapeutics, Inc. $FULC

First Turn Management LLC bought a new position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 1,892,683 shares of the company’s stock, valued at approximately $21,406,000. Fulcrum Therapeutics accounts for approximately 2.4% of First Turn Management LLC’s holdings, making the stock its 20th biggest position.

Several other hedge funds and other institutional investors also recently made changes to their positions in FULC. Cubist Systematic Strategies LLC acquired a new position in shares of Fulcrum Therapeutics in the first quarter worth about $164,000. Jane Street Group LLC boosted its holdings in shares of Fulcrum Therapeutics by 62.1% during the first quarter. Jane Street Group LLC now owns 117,816 shares of the company’s stock worth $339,000 after purchasing an additional 45,157 shares during the period. Creative Planning acquired a new stake in shares of Fulcrum Therapeutics during the second quarter worth approximately $117,000. Legal & General Group Plc boosted its holdings in shares of Fulcrum Therapeutics by 230.2% during the second quarter. Legal & General Group Plc now owns 17,461 shares of the company’s stock worth $120,000 after purchasing an additional 12,173 shares during the period. Finally, American Century Companies Inc. boosted its holdings in shares of Fulcrum Therapeutics by 7.0% during the second quarter. American Century Companies Inc. now owns 132,349 shares of the company’s stock worth $911,000 after purchasing an additional 8,638 shares during the period. 89.83% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Piper Sandler cut shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating and set a $3.00 price target for the company. in a report on Tuesday, June 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Tuesday, April 21st. JPMorgan Chase & Co. cut shares of Fulcrum Therapeutics from an “overweight” rating to an “underweight” rating in a report on Wednesday, June 3rd. Stifel Nicolaus cut shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $3.00 price target for the company. in a report on Tuesday, June 2nd. Finally, Citigroup cut shares of Fulcrum Therapeutics from an “underperform” rating to an “underweight” rating in a report on Tuesday, June 2nd. One equities research analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and four have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Reduce” and an average price target of $8.20.

Fulcrum Therapeutics Stock Performance

FULC stock opened at $3.45 on Friday. The stock has a market cap of $229.87 million, a P/E ratio of -3.00 and a beta of 2.93. The firm has a 50 day simple moving average of $6.59 and a 200 day simple moving average of $8.82. Fulcrum Therapeutics, Inc. has a 52 week low of $2.83 and a 52 week high of $15.74.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings data on Monday, April 27th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.06. Sell-side analysts predict that Fulcrum Therapeutics, Inc. will post -0.76 EPS for the current year.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.